Search results for "Anti-inflammatory agents"

showing 10 items of 576 documents

Retrospective analysis of fixed drug eruptions among patients attending a tertiary care center in Southern India

2014

AdultMalemedicine.medical_specialtyAdolescentIndiaDermatologyTertiary careTertiary Care CentersYoung Adultlcsh:DermatologyRetrospective analysisHumansMedicineCenter (algebra and category theory)Fixed drug eruptionsAgedRetrospective Studiesbusiness.industryAnti-Inflammatory Agents Non-SteroidalMiddle Agedlcsh:RL1-803medicine.diseaseAnti-Bacterial AgentsInfectious DiseasesEmergency medicineFemaleDrug EruptionsMedical emergencybusinessIndian Journal of Dermatology, Venereology, and Leprology
researchProduct

Endogenous opioid peptide responses to opioid and anti-inflammatory medications following eccentric exercise-induced muscle damage.

2009

To determine the effects of Vicoprofen, Ibuprofen, and a placebo on the responses of endogenous opioid peptides following eccentric exercise-induced muscle damage 36 healthy men (age: 22.8 years; height: 178.8+/-6.2cm; body mass: 78.9+/-13.7kg; body fat: 15.8+/-6.5%) volunteered to participate in the study. Each participant was evaluated for pain 24h post and randomly assigned to an experimental group: VIC (Vicoprofen), IBU (Ibuprofen), or P (placebo). Medication was given four times daily (i.e., VIC (hydrocodone bitartrate 7.5mg with Ibuprofen 200mg) and IBU 200mg). Blood was obtained at rest and at 0, 24, 48, 72, 96 and 120h following the eccentric exercise damage protocol. No significant…

AdultMalemedicine.medical_specialtyAdolescentPhysiologyPhysical ExertionAnti-Inflammatory AgentsPainPhysical exercisePlaceboBiochemistryPlacebosCellular and Molecular NeuroscienceYoung AdultEndocrinologyDouble-Blind MethodInternal medicinemedicineEccentricAnimalsHumansOpioid peptideMuscle SkeletalExerciseEndogenous opioidPain MeasurementChemistryIbuprofenMagnetic Resonance ImagingEndocrinologymedicine.anatomical_structureOpioidOpioid PeptidesAdrenal medullamedicine.drugPeptides
researchProduct

Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy

2014

Abstract Background Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. Methods One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall co…

AdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIAmedicine.medical_treatmentUlcerative colitis;GastroenterologyDrug Administration ScheduleYoung AdultAdrenal Cortex HormonesInternal medicineHumansMedicineTreatment FailureAdverse effectColectomyInfliximab;AgedColectomyIntention-to-treat analysisbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologyAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisInfliximabInfliximabRegimenTreatment OutcomeUlcerative colitisRelative riskCohortColitis UlcerativeFemalebusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

A European multicentre photopatch test study

2012

The two most common agent groups currently responsible for photoallergic contact dermatitis (PACD) are organic ultraviolet (UV) absorbers in sunscreens and topical nonsteroidal anti-inflammatory drugs (NSAIDs). However, availability of information on the photoallergenic potential of these agents is scarce.To obtain current information on the frequency of PACD to 19 organic UV absorbers and five topical NSAIDs, including newer agents, in common usage in Europe.A prospective, multicentre photopatch test study was conducted with 1031 patients attending for investigation of suspected PACD in 30 centres across 12 European countries.A total of 346 PACD reactions in 200 (19·4%) subjects occurred. …

AdultMalemedicine.medical_specialtyAdolescentUltraviolet RaysPhotopatch testPhotoallergic Contact DermatitisSunscreening AgentsDermatologyYoung AdultmedicineHumansProspective StudiesYoung adultProspective cohort studyAgedAged 80 and overPhotosensitizing AgentsDermatitis Photoallergicbusiness.industryAnti-Inflammatory Agents Non-SteroidalPhotosensitizing AgentMiddle AgedPatch TestsDermatologySurgeryEuropePhotoallergensFemalebusinessSunscreening AgentsBritish Journal of Dermatology
researchProduct

Psoriatic arthritis onset in psoriatic patients receiving UV phototherapy in Italy

2018

Abstract BACKGROUND: Psoriasis is a chronic, recurrent, and immune-mediated inflammatory disease that affects 2-3% of the world population. A substantial proportion of patients with psoriasis, approximately 40 %, develop a form of inflammatory arthritis known as psoriatic arthritis (PsA), the arthritis follows the development of psoriasis, and it will develop simultaneously or possibly before the appearance of skin lesions. The presence of PsA indicates a need for more active intervention rather than purely topical therapies or UV-based therapies. The aim of this multicenter, retrospective, epidemiological study was to estimate the incidence of PsA in psoriatic patients receiving UV treatme…

AdultMalemedicine.medical_specialtyAlcohol DrinkingInflammatory arthritisAnti-Inflammatory AgentsArthritisDermatologyComorbidityAsymptomatic030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritis0302 clinical medicineRisk FactorsPsoriasismedicineHumansPsoriasisObesityMetabolic SyndromePast medical historybusiness.industryIncidence (epidemiology)Arthritis PsoriaticSmokingMiddle Agedmedicine.diseaseDermatologyAdipose TissueCardiovascular DiseasesPsoriatic arthritisPopulation studyCytokinesFemaleUltraviolet Therapymedicine.symptomWaist CircumferencebusinessImmunosuppressive Agents
researchProduct

Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis

2008

Psoriasis and psoriatic arthritis are common diseases associated with considerable morbidity and disability. Their pathophysiology comprises similar processes leading to inflammation of skin, entheses, and joints. Although traditional systemic agents can be effective, their use may be limited by lack of efficacy and concerns regarding adverse effects. The objective of this study was to assess the efficacy and safety of adalimumab, a fully human antitumor necrosis factor (anti-TNF) monoclonal antibody, over 16 weeks. The present authors report their personal experience in 15 patients with severe plaque psoriasis and psoriatic arthritis, refractory to other treatments, in which a decisive reg…

AdultMalemedicine.medical_specialtyAnti-Inflammatory AgentsArthritisDermatologyAntibodies Monoclonal HumanizedSeverity of Illness IndexPsoriasis Psoriatic ArthritisPsoriatic arthritisPsoriasisSeverity of illnessSettore MED/35 - Malattie Cutanee E VenereemedicineAdalimumabHumansPsoriasisAdverse effectTumor Necrosis Factor-alphabusiness.industryArthritis PsoriaticAdalimumabAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseDermatologyRadiographyClinical trialTreatment OutcomeMonoclonalFemalebusinessmedicine.drugDermatologic Therapy
researchProduct

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observ…

2018

BACKGROUND: European guidelines recommend intravenous methylprednisolone as first-line treatment for active and severe Graves' orbitopathy; however, it is common for patients to have no response or have relapse after discontinuation of treatment. We aimed to compare the efficacy and safety of add-on mycophenolate to methylprednisolone in comparison with methylprednisolone alone in patients with moderate-to-severe Graves' orbitopathy.METHODS: MINGO was an observer-masked, multicentre, block-randomised, centre-stratified trial done in two centres in Germany and two in Italy. Patients with active moderate-to-severe Graves' orbitopathy were randomly assigned to receive intravenous methylprednis…

AdultMalemedicine.medical_specialtyCombination therapyAdolescentEndocrinology Diabetes and MetabolismPopulationMedizinAnti-Inflammatory Agents030209 endocrinology & metabolismMethylprednisoloneSeverity of Illness IndexMycophenolic acidlaw.inventionGraves' ophthalmopathy03 medical and health sciencesYoung Adult0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodlawInternal medicineJournal ArticleInternal MedicinemedicineHumanseducationAdverse effectAgededucation.field_of_studyAntibiotics Antineoplasticbusiness.industryMiddle AgedMycophenolic Acidmedicine.diseaseDiscontinuationGraves OphthalmopathyTreatment OutcomeMethylprednisoloneItaly030221 ophthalmology & optometryDrug Therapy CombinationFemalebusinessmedicine.drugThe lancet. Diabetesendocrinology
researchProduct

Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms

2016

SummaryAim The aim of this study was to explore factors affecting efficacy of treatment of common cold symptoms with an over-the-counter ibuprofen/pseudoephedrine combination product. Methods Data from an anonymous survey among 1770 pharmacy customers purchasing the combination product for treatment of own common cold symptoms underwent post-hoc descriptive analysis. Scores of symptoms typically responsive to ibuprofen (headache, pharyngeal pain, joint pain and fever), typically responsive to pseudoephedrine (congested nose, congested sinus and runny nose), considered non-specific (sneezing, fatigue, dry cough, cough with expectoration) and comprising all 11 symptoms were analysed. Multiple…

AdultMalemedicine.medical_specialtyCommon ColdInfectious DiseaseIbuprofenNonprescription DrugsPharmacy030226 pharmacology & pharmacyDrug Administration Schedule03 medical and health sciences0302 clinical medicineExpedited Clinical TrialSurveys and QuestionnairesInternal medicinemedicineHumans030223 otorhinolaryngologyNosePain Measurementbusiness.industryAnti-Inflammatory Agents Non-SteroidalCommon coldmultiple regression analysisGeneral MedicinePseudoephedrinemedicine.diseaseIbuprofenPseudoephedrinesymptom scoreNasal decongestantNasal DecongestantsTreatment Outcomemedicine.anatomical_structureAnesthesiaJoint painDrug Therapy CombinationFemalemedicine.symptombusinessmedicine.drugCombination drugInternational Journal of Clinical Practice
researchProduct

Postoperative pain therapy after lumbar disc surgery.

2000

Object. This study was undertaken to determine whether a special postoperative pain administration of tramadol and diclofenac provides any benefits in patients who underwent microsurgical lumbar discectomy.  Methods. The study consisted of 60 patients undergoing microsurgical lumbar discectomy. Patients were randomly divided into two groups based on the postoperative pain management: 1) Group A (n=30): no standardized pain therapy; these patients received on demand different analgesics and at variable dosages which were selected by the neurosurgeons; 2) Group B (n=30): standardized pain therapy with specific dosages of tramadol and diclofenac in regular time intervals during the first 48 ho…

AdultMalemedicine.medical_specialtyDiclofenacAnalgesicPainLumbar vertebraeDiclofenacPostoperative ComplicationsmedicineHumansHerniaIntervertebral DiscTramadolAgedPain MeasurementLumbar Vertebraemedicine.diagnostic_testbusiness.industryAnti-Inflammatory Agents Non-SteroidalInterventional radiologyMiddle Agedmedicine.diseaseSurgeryAnalgesics OpioidIntervertebral diskmedicine.anatomical_structureAnesthesiaSurgeryDrug Therapy CombinationFemaleNeurology (clinical)TramadolComplicationbusinessmedicine.drugDiskectomyActa neurochirurgica
researchProduct

Surgery during etanercept therapy in patients with rheumatoid arthritis: is it time to follow patient preferences?

2008

Tumor necrosis factor (TNF)-a inhibitors, such as etanercept and infliximab, improve symptoms and function in patients affected by rheumatoid arthritis (RA) [1, 2] and, therefore, are playing an increasing role in the management of this disease. However, interference with endogenous TNF-a signalling has been reported to alter both normal inflammatory responses in tissue healing and infection surveillance [2, 3]. To our knowledge, the rates of surgery in RA are decreasing. However, with the duration of antiTNF therapy, the number of patients under these agents having surgery will be increasing. These data raise the question of whether TNF-inhibitors can be safely used in RA patients who shou…

AdultMalemedicine.medical_specialtyDiseaseReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidPostoperative ComplicationsInternal MedicinemedicineOutpatient clinicHumansElective surgeryWound Healingbusiness.industryContraindicationsAnti-Inflammatory Agents Non-SteroidalMiddle Agedmedicine.diseaseInfliximabSurgeryItalyPatient SatisfactionRheumatoid arthritisImmunoglobulin GSurgical Procedures OperativeCohortEmergency MedicineQuality of LifeMethotrexateFemalebusinessmedicine.drugInternal and emergency medicine
researchProduct